Abstract:Background Anti-PD-1(L1) therapies are less efficacious in patients with EGFR -mutated non-small-cell lung cancer. However, the underlying mechanism is poorly understood. Methods The characteristics of T cells in EGFR -mutated and wild-type tumors were analyzed based on The Cancer Genome Atlas database and clinical samples. Plasma levels of 8 T-cell-related cytokines were evaluated and its association with immunotherapy efficacy were explored. Association between EGFR signaling pathway and IL-10 was examined through tumor cell lines and clinical tumor samples. In vitro restimulation model of human CD8 + T cells isolated from peripheral blood was used to analyze the impact of IL-10 on T cells. Doxycycline-inducible transgenic EGFR L858R mouse models were used to investigate the efficacy of combining recombinant mouse IL-10 protein and PD-1 blockade and its underlying mechanism in vivo . Results EGFR -mutated tumors showed a lack of CD8 + T cell infiltration and impaired CD8 + T cell cytotoxic function. The incompetent CD8 + T cells in EGFR -mutated tumors were characterized as absence of CD39 expression, which defined hallmarks of cytotoxic and exhausted features and could not be reinvigorated by anti-PD-1(L1) treatment. Instead, CD39 expression defined functional states of CD8 + T cells and was associated with the therapeutic response of anti-PD-1(L1) therapies. Mechanically, IL-10 upregulated CD39 expression and was limited in EGFR -mutated tumors. IL-10 induced hallmarks of CD8 + T cells immunity in CD39-dependent manner. Using autochthonous EGFR L858R -driven lung cancer mouse models, combining recombinant mouse IL-10 protein and PD-1 blockade optimized antitumor effects in EGFR -mutated lung tumors. Conclusions Our study suggested that owing to low level of IL-10 to induce the expression of CD39 on CD8 + T cells, fewer phenotypically cytotoxic and exhausted CD39 + CD8 + T cells in EGFR -mutated tumors could be potentially reinvigorated by anti-PD-1(L1) treatment. Hence, IL-10 could potentially serve as a cytokine-based strategy to enhance efficacy of anti-PD-1(L1) treatment in EGFR -mutated tumors.

Regulation of IL-10 expression and function by JAK-STAT in CD8 + T cells

Il-10 Enhances Ctl-Mediated Tumor Rejection By Inhibiting Highly Suppressive Cd4(+) T Cells And Promoting Ctl Persistence In A Murine Model Of Plasmacytoma

Data from Autocrine Complement Inhibits IL10-Dependent T-cell–Mediated Antitumor Immunity to Promote Tumor Progression

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Interleukin 10 enhanced CD8+ T cell activity and reduced CD8+ T cell apoptosis in patients with diffuse large B cell lymphoma

A Regulatory Role for IL-10 Receptor Signaling in Development and B Cell Help of T Follicular Helper Cells in Mice

Stimulatory Role of Interleukin 10 in CD8+ T Cells Through STATs in Gastric Cancer

IL-10 Has A Distinct Immunoregulatory Effect on Naive and Active T Cell Subsets

Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism

Proteomics analysis reveals the interleukin-35-dependent regulatory mechanisms affecting CD8<SUP>+</SUP> T-cell functions

An IL-27-Driven Transcriptional Network Identifies Regulators of IL-10 Expression across T Helper Cell Subsets

IL-4 Induces a Suppressive IL-10-producing CD8+ T Cell Population Via a Cdkn2a-dependent Mechanism.

Progress on Interleukin-10

IL-2 Can Signal Via Chemokine Receptors to Promote Regulatory T Cells' Suppressive Function.

JAK/STAT Signaling Pathway Mediates Anti-Tumor Immunity of CD8+ T Cells in Renal Cancer

Supplementary Methods, Figures S1 - S4 from Autocrine Complement Inhibits IL10-Dependent T-cell–Mediated Antitumor Immunity to Promote Tumor Progression

Reprogramming of IL-10 Activity and Signaling by IFN-γ

The regulation of IL-10 production by immune cells

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer

Interleukin 10 Promotes Immune Response by Increasing the Survival of Activated CD8+ T Cells in Human Papillomavirus 16-Infected Cervical Cancer

Functional Analysis of Stat4 in Tumor Immunity by Inhibitory Jak/Stat in Vitro